- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Interventions
- letrozole, gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, breast biopsy, diagnostic laboratory biomarker analysis, pharmacological study
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
- Interventions
- Not listed
- Lead sponsor
- Exact Sciences Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Scarborough, Maine • Murfreesboro, Tennessee + 1 more
- Conditions
- Breast Cancer
- Interventions
- 6 Gy/ fraction
- Radiation
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Osteoporosis
- Interventions
- ALX1-11 (drug)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 1,683 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more
- Conditions
- Alzheimer Disease
- Interventions
- Donepezil, Estrogen, Progesterone
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 45 Years to 85 Years · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Post-menopausal Vasomotor Symptoms
- Interventions
- BAY3427080, Placebo (for BAY3427080)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- DeLand, Florida • Miami, Florida • San Antonio, Texas
- Conditions
- Menopause
- Interventions
- TSEC (Tissue-selective estrogen complexes), Placebo
- Drug · Other
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 50 Years to 60 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Dapivirine Vaginal Ring, Placebo Vaginal Ring
- Drug
- Lead sponsor
- International Partnership for Microbicides, Inc.
- Industry
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
- Interventions
- Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Recurrent UTIs, Recurrent Urinary Tract Infections, Recurrent Urinary Tract Infections in Women, Recurrent Urinary Tract Infection, Cystitis Recurrent, Cystitis Chronic, UTI, UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection
- Interventions
- D-Mannose, Placebo
- Dietary Supplement
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 55 Years to 85 Years · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Menopause, Menopause Hot Flashes, Menopause Related Conditions
- Interventions
- Haelan 951
- Dietary Supplement
- Lead sponsor
- Spectrum Clinical Research, LLC
- Network
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
- Drug
- Lead sponsor
- VIVUS LLC
- Industry
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Breast Cancer
- Interventions
- letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Little Rock, Arkansas • Grass Valley, California + 43 more
- Conditions
- Menopause, Hot Flashes
- Interventions
- Shatavari (Asparagus racemosus) Extract, Placebo
- Dietary Supplement · Other
- Lead sponsor
- India Glycols Ltd
- Industry
- Eligibility
- 45 Years to 60 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Port Richey, Florida
- Conditions
- Healthy Volunteer Study
- Interventions
- SCO-120, matching placebo
- Drug
- Lead sponsor
- Sun Pharma Advanced Research Company Limited
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Dilworth, Minnesota • Creve Coeur, Missouri
- Conditions
- Hormone Receptor Positive Early Breast Cancer
- Interventions
- US-sourced oral Femara® + Letrozole SIE, EU sourced oral Femara® + Letrozole SIE
- Drug
- Lead sponsor
- Rovi Pharmaceuticals Laboratories
- Industry
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Margate, Florida • Port Orange, Florida
- Conditions
- Healthy Postmenopausal Women
- Interventions
- KSHN001126 150mg, KSHN001126 300mg, KSHN001126 600mg
- Drug
- Lead sponsor
- Amneal Pharmaceuticals, LLC
- Industry
- Eligibility
- 45 Years to 60 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cancer
- Interventions
- fatigue assessment and management, management of therapy complications, psychosocial assessment and care
- Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 9
- States / cities
- Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more
- Conditions
- Osteopenia, Osteoporosis
- Interventions
- BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 45 Years to 85 Years · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 5
- States / cities
- Anaheim, California • Miami, Florida • Berlin, New Jersey + 1 more
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- estrogen
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1985 – 1989
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Dyspareunia
- Interventions
- Prasterone
- Drug
- Lead sponsor
- San Diego Sexual Medicine
- Other
- Eligibility
- 21 Years to 80 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction, Dyspareunia, Vulvodynia, Vestibulodynia, Arousal Disorders, Sexual, Genito-Pelvic Pain/Penetration Disorder, Female Sexual Arousal Disorder
- Interventions
- 5% sinecatechins ointment, Placebo, 10% sinecatechins ointment
- Drug
- Lead sponsor
- GTO Pharmaceutical, LLC
- Other
- Eligibility
- 20 Years to 70 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- New York, New York • Nyack, New York
- Conditions
- Vasomotor Symptoms (VMS) Associated With Menopause
- Interventions
- No study intervention
- Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Risk Reduction, Breast Cancer
- Interventions
- Bazedoxifene and Conjugated Estrogens
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 45 Years to 64 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Duarte, California • San Francisco, California • Chicago, Illinois + 3 more